×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
FBIO – fortress biotech, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
FBIO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/16
07:20 am
fbio
Fortress Biotech (NASDAQ:FBIO) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Fortress Biotech (NASDAQ:FBIO) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/13
07:45 am
fbio
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
High
Report
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
12/15
08:10 am
fbio
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission [Yahoo! Finance]
Medium
Report
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission [Yahoo! Finance]
12/15
08:00 am
fbio
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
High
Report
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
12/9
04:24 pm
fbio
Fortress Biotech (NASDAQ:FBIO) had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Fortress Biotech (NASDAQ:FBIO) had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings.
11/23
02:11 am
fbio
Fortress Biotech (NASDAQ:FBIO) was upgraded by analysts at Wall Street Z
Low
Report
Fortress Biotech (NASDAQ:FBIO) was upgraded by analysts at Wall Street Z
11/14
09:35 am
fbio
Fortress Biotech GAAP EPS of $0.11, revenue of $17.6M [Seeking Alpha]
Medium
Report
Fortress Biotech GAAP EPS of $0.11, revenue of $17.6M [Seeking Alpha]
11/14
08:41 am
fbio
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
Medium
Report
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/13
09:20 am
fbio
Form 8-K Fortress Biotech, Inc. For: Jan 13
Medium
Report
Form 8-K Fortress Biotech, Inc. For: Jan 13
1/5
04:31 pm
fbio
Form 4 Fortress Biotech, Inc. For: Jan 01 Filed by: Klein Dov
Low
Report
Form 4 Fortress Biotech, Inc. For: Jan 01 Filed by: Klein Dov
1/5
04:31 pm
fbio
Form 4 Fortress Biotech, Inc. For: Jan 01 Filed by: Lorenz Kevin
Low
Report
Form 4 Fortress Biotech, Inc. For: Jan 01 Filed by: Lorenz Kevin
1/5
04:31 pm
fbio
Form 4 Fortress Biotech, Inc. For: Jan 01 Filed by: LOBELL J JAY
Low
Report
Form 4 Fortress Biotech, Inc. For: Jan 01 Filed by: LOBELL J JAY
1/5
04:31 pm
fbio
Form 4 Fortress Biotech, Inc. For: Jan 01 Filed by: Hoenlein Malcolm
Low
Report
Form 4 Fortress Biotech, Inc. For: Jan 01 Filed by: Hoenlein Malcolm
1/5
04:31 pm
fbio
Form 4 Fortress Biotech, Inc. For: Jan 01 Filed by: Harvey Jimmie
Low
Report
Form 4 Fortress Biotech, Inc. For: Jan 01 Filed by: Harvey Jimmie
12/18
04:06 pm
fbio
Form 424B3 Fortress Biotech, Inc.
Medium
Report
Form 424B3 Fortress Biotech, Inc.
12/18
06:05 am
fbio
Form EFFECT Fortress Biotech, Inc.
Medium
Report
Form EFFECT Fortress Biotech, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/16
Fortress Biotech Reports Record Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Highlights
21.1%
3/24 Fortress Biotech (NASDAQ: FBIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. 15.7%
11/10 Do Insiders Own Shares In Fortress Biotech, Inc. (NASDAQ:FBIO)? [Yahoo! Finance News] 15.3%
8/23 Form 424B3 Fortress Biotech, Inc. 14.6%
7/19 Form 4 Fortress Biotech, Inc. For: Jul 18 Filed by: ROSENWALD LINDSAY A MD 12.3%
1/16 Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes Disease 11.1%
12/10 Form 3 Fortress Biotech, Inc. For: Aug 14 Filed by: Lorenz Kevin 10.0%
12/18 Fortress Biotech (NASDAQ: FBIO) is now covered by analysts at B. Riley. They set a "buy" rating and a $9.00 price target on the stock. 8.0%
11/12 Form FWP Fortress Biotech, Inc. Filed by: Fortress Biotech, Inc. 7.9%
5/10 Q1/2019 3/31/2019 EPS -0.340 ZacksConsensus -0.580 ActVsEst 0.240 - Beat 7.9%
3/24 Fortress Biotech (NASDAQ: FBIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. 15.7%
11/10 Do Insiders Own Shares In Fortress Biotech, Inc. (NASDAQ:FBIO)? [Yahoo! Finance News] 15.3%
8/23 Form 424B3 Fortress Biotech, Inc. 14.6%
7/19 Form 4 Fortress Biotech, Inc. For: Jul 18 Filed by: ROSENWALD LINDSAY A MD 12.3%
1/16 Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes Disease 11.1%
12/10 Form 3 Fortress Biotech, Inc. For: Aug 14 Filed by: Lorenz Kevin 10.0%
12/18 Fortress Biotech (NASDAQ: FBIO) is now covered by analysts at B. Riley. They set a "buy" rating and a $9.00 price target on the stock. 8.0%
11/12 Form FWP Fortress Biotech, Inc. Filed by: Fortress Biotech, Inc. 7.9%
5/10 Q1/2019 3/31/2019 EPS -0.340 ZacksConsensus -0.580 ActVsEst 0.240 - Beat 7.9%
TOP News Decliners
3/13
Form 4 Fortress Biotech, Inc. For: Jan 01 Filed by: Rowinsky Eric K
-18.6%
8/9 Form S-8 Fortress Biotech, Inc. -15.3%
5/10 Form 10-Q Fortress Biotech, Inc. For: Mar 31 -10.1%
3/7 As Bad as Rout Is, Most Investors See Recession as a Long Shot [Yahoo! Finance News] -9.5%
7/16 Fortress Biotech (NASDAQ: FBIO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.6%
2/1 Fortress Biotech (NASDAQ: FBIO) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -5.1%
1/13 Journey Medical Corporation Recaps 2019 Growth -4.0%
2/14 Form SC 13G/A Fortress Biotech, Inc. Filed by: Opaleye Management Inc. -2.7%
5/16 Fortress Biotech (NASDAQ: FBIO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. -2.6%
11/25 Fortress Biotech Announces Pricing of Series A Preferred Stock Offering -2.5%
8/9 Form S-8 Fortress Biotech, Inc. -15.3%
5/10 Form 10-Q Fortress Biotech, Inc. For: Mar 31 -10.1%
3/7 As Bad as Rout Is, Most Investors See Recession as a Long Shot [Yahoo! Finance News] -9.5%
7/16 Fortress Biotech (NASDAQ: FBIO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.6%
2/1 Fortress Biotech (NASDAQ: FBIO) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -5.1%
1/13 Journey Medical Corporation Recaps 2019 Growth -4.0%
2/14 Form SC 13G/A Fortress Biotech, Inc. Filed by: Opaleye Management Inc. -2.7%
5/16 Fortress Biotech (NASDAQ: FBIO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. -2.6%
11/25 Fortress Biotech Announces Pricing of Series A Preferred Stock Offering -2.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: